A century of traditional vaccinology lost the fight against meningococcus 
serogroup B (MenB). However, thanks to an innovative genome-based approach, the 
first broadly effective MenB vaccine, Bexsero® (GSK Vaccines), was developed and 
has been licensed for use in various age groups by the European Commission and 
other regulatory authorities. Genes encoding for the main meningococcus B 
antigens were identified and screened in order to achieve a broadly protective 
vaccine, taking into account the fact that meningococcus B has many different 
subtypes whose membrane proteins may be different. Since the antigens selected 
for Bexsero® are also harbored by meningococci belonging to other serogroups 
there may be the potential for Bexsero® to offer a certain level of protection 
against non-B serogroups. Therefore preliminary studies were carried out to 
investigate the potential of the vaccine to also provide a degree of cross 
protection against non-B serogroups. Here we review the potential for Bexsero® 
to offer a certain level of protection against the diversity of meningococcus 
type B subtypes and its potential ability to offer some cross protection from 
non-B serogroups. Lastly, we describe the future perspectives in pentavalent 
meningococcal vaccine (ABCWY) development which hopefully will result in a 
vaccine able to help prevent Invasive Meningococcal Diseases (IMD) from the 
majority of currently circulating meningococcal strains.